Ganter Michael T, Ware Lorraine B, Howard Marybeth, Roux Jérémie, Gartland Brandi, Matthay Michael A, Fleshner Monika, Pittet Jean-François
Department of Anesthesia, University of California, San Francisco, 94110, USA.
Am J Physiol Lung Cell Mol Physiol. 2006 Sep;291(3):L354-61. doi: 10.1152/ajplung.00405.2005. Epub 2006 May 5.
Previous studies have shown that heat shock protein 72 (Hsp72) is found in the extracellular space (eHsp72) and that eHsp72 has potent immunomodulatory effects. However, whether eHsp72 is present in the distal air spaces and whether eHsp72 could modulate removal of alveolar edema is unknown. The first objective was to determine whether Hsp72 is released within air spaces and whether Hsp72 levels in pulmonary edema fluid would correlate with the capacity of the alveolar epithelium to remove alveolar edema fluid in patients with ALI/ARDS. Patients with hydrostatic edema served as controls. The second objective was to determine whether activation of the stress protein response (SPR) caused the release of Hsp72 into the extracellular space in vivo and in vitro and to determine whether SPR activation and/or eHsp72 itself would prevent the IL-1beta-mediated inhibition of the vectorial fluid transport across alveolar type II cells. We found that eHsp72 was present in plasma and pulmonary edema fluid of ALI patients and that eHsp72 was significantly higher in pulmonary edema fluid from patients with preserved alveolar epithelial fluid clearance. Furthermore, SPR activation in vivo in mice and in vitro in lung endothelial, epithelial, and macrophage cells caused intracellular expression and extracellular release of Hsp72. Finally, SPR activation, but not eHsp72 itself, prevented the decrease in alveolar epithelial ion transport induced by exposure to IL-1beta. Thus SPR may protect the alveolar epithelium against oxidative stress associated with experimental ALI, and eHsp72 may serve as a marker of SPR activation in the distal air spaces of patients with ALI.
先前的研究表明,热休克蛋白72(Hsp72)存在于细胞外空间(eHsp72),且eHsp72具有强大的免疫调节作用。然而,eHsp72是否存在于远端气腔以及eHsp72能否调节肺泡水肿的清除尚不清楚。第一个目标是确定Hsp72是否在气腔内释放,以及急性肺损伤/急性呼吸窘迫综合征(ALI/ARDS)患者肺水肿液中的Hsp72水平是否与肺泡上皮清除肺泡水肿液的能力相关。以静水压性水肿患者作为对照。第二个目标是确定应激蛋白反应(SPR)的激活是否会在体内和体外导致Hsp72释放到细胞外空间,并确定SPR激活和/或eHsp72本身是否会阻止白细胞介素-1β(IL-1β)介导的跨II型肺泡细胞的向量性液体转运抑制。我们发现,eHsp72存在于ALI患者的血浆和肺水肿液中,且在肺泡上皮液体清除功能保留的患者的肺水肿液中eHsp72显著更高。此外,小鼠体内以及肺内皮细胞、上皮细胞和巨噬细胞体外的SPR激活导致了Hsp72的细胞内表达和细胞外释放。最后,SPR激活而非eHsp72本身阻止了暴露于IL-1β引起的肺泡上皮离子转运减少。因此,SPR可能保护肺泡上皮免受与实验性ALI相关的氧化应激,且eHsp72可能作为ALI患者远端气腔中SPR激活的标志物。